Open AccessA Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality
Author(s) -
Ana FernándezCruz,
Belén Ruíz-Antorán,
Ana Muñoz Gómez,
Aránzazu Sancho-López,
Patricia Mills-Sánchez,
Gustavo Adolfo Centeno-Soto,
Silvia BlancoAlonso,
Laura Javaloyes-Garachana,
Amy Galán Gómez,
Ángela Valencia-Alijo,
Javier Gómez-Irusta,
Concepción Payares-Herrera,
Ignacio Morrás-Torre,
Enrique Sánchez-Chica,
Laura Delgado-Téllez-de-Cepeda,
Alejandro CallejasDíaz,
Antonio RamosMartínez,
Elena MúñezRubio,
Cristina Avendaño-Solá
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01168-20
Subject(s) - medicine , retrospective cohort study , interquartile range , hazard ratio , pneumonia , confidence interval , methylprednisolone , propensity score matching , cohort study
Evidence to support the use of steroids in coronavirus disease 2019 (COVID-19) pneumonia is lacking. We aim to determine the impact of steroid use for COVID-19 pneumonia on hospital mortality. We performed a single-center retrospective cohort study in a university hospital in Madrid, Spain, during March of 2020. To determine the role of steroids in in-hospital mortality, patients admitted with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and treated with steroids were compared to patients not treated with steroids, and we adjusted with a propensity score for patients on steroid treatment.